James Ahlers Email Address

Chief Financial Officer

Intarcia Therapeutics, Inc., incorporated in June 1995, is a biopharmaceutical company with an approach to acquire, develop and commercialize therapeutic products for the treatment of cancer and infectious diseases. The Company is developing atamestane, its aromatase inhibitor, in combination with toremifene, an approved estrogen receptor blocker, for the treatment of hormone-dependent breast cancer in postmenopausal women. During the year ended December 31, 2004, Intarcia Therapeutics, Inc. was in Phase III clinical development with this combination for the initial or first line treatment of hormone-dependent advanced (metastatic or locally advanced) breast cancer in postmenopausal women. It is developing omega DUROS, a subcutaneous implant designed to deliver its omega interferon, for the treatment of hepatitis C. The Company has completed a Phase II clinical trial of omega interferon.

'Think forward and reason back.' James applies that principle from his legal education--along with his past experience as a litigator, journalist, policy analyst, and press secretary for the Arizona Governor's Office--to provide holistic yet straightforward solutions to complex legal and policy challenges. James has served a diverse set of clients, including small businesses, traditional and digital media, real estate interests, and government entities. James has authored briefs to the U.S. Supreme Court and the Federal, Fifth, Seventh and Ninth Circuit Courts of Appeals, and the Delaware Supreme Court. James is proud to have represented several clients pro bono in immigration and civil rights matters.